Comparative Pharmacology
Head-to-head clinical analysis: DELTA CORTEF versus KENALOG IN ORABASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTA CORTEF versus KENALOG IN ORABASE.
DELTA-CORTEF vs KENALOG IN ORABASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Prednisolone (DELTA-CORTEF) typical adult dose: 5-60 mg orally once daily or in divided doses, depending on condition. For acute exacerbations: 20-60 mg orally daily. Route: oral. Frequency: once daily or divided.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
None Documented
None Documented
Terminal elimination half-life: 1.5-2.5 hours (mean ~2 hours) for prednisolone; clinical context: short-acting glucocorticoid, requires multiple daily dosing for sustained anti-inflammatory effect, adrenocortical suppression lasts approximately 1.25-1.5 days after discontinuation.
Terminal half-life approximately 2-5 hours following mucosal application.
Renal: approximately 80-90% as unchanged drug and metabolites (primarily 20β-dihydrocortisone and other inactive conjugates); biliary/fecal: <10%.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Category C
Category C
Corticosteroid
Corticosteroid